Texas Biotech (TXB) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Texas Biotech (TXB)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Don Cheng who wrote (197)	6/8/1997 7:24:00 PM
From: Bharat H. Barai	of 834

Texas Biotech is presenting data on Novastan for Heparin induced Thrombocytopenis on June 12 at Internationa Thrombosis Conference in Florence, Italy. the Company already issued a press release that the drug is effective and achieved statistical significant difference. They are to file NDA with FDA sometimes in next 10-45 days. The drug should be approved on fast track as there is no other drug to take care of patients who develop Heparin induced Thrombocytopenia. I doubt it will take more than 3-4 months to get approval. Texas Biotech has already stated that they donot plan to market the drug themselves but tie up with a big company as marketing partner. They are already negotiating with some of them. hard to say when the final decision will be announced. but with such positive data, they should have plenty of companies lining up. Their cash position should be more than adequate to take them thru FDA approval. The drug is already in use in Japan for lst 3 years, so no unknown surprise side effects are likely to surface. Bharat Barai MD Hematologist

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next